Previous 10 | Next 10 |
IMV (NASDAQ:IMV): Q3 GAAP EPS of -$0.13 misses by $0.01. Revenue of $0.04M (-55.6% Y/Y) misses by $0.02M. Press Release For further details see: IMV EPS misses by $0.01, misses on revenue
IMV Inc. (“IMV” or “the Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing immune-educating cancer therapies, based on its novel DPX platform, that target solid and blood cancers while preserving patients’ quality of life, today ann...
IMV (NASDAQ:IMV) is scheduled to announce Q3 earnings results on Thursday, November 11th, before market open. The consensus EPS Estimate is -$0.12 (+7.7% Y/Y) and the consensus Revenue Estimate is $0.06M (-33.3% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 2 dow...
AEG, OTCQX:ALEAF, AMTX, AYRO, AZUL, BAM, BGRY, CAE, CELH, OTCQX:CRLBF, DCBO, OTCQX:EDVMF, GRWG, HUT, IMV, OTCPK:MKGAF, NICE, NVVE, OGN, PSFE, QSI, RSLS, RWLK, SBH, SPCB, SPH, STNG, STXS, THRY, TMDI, TPR, TXMD, UTZ, VNRX, WB, WIX, WWR, XNET, YETI For Seeking Alpha's full earnings season calend...
MVP-S treatment increased survivin-specific T and B cell tumor infiltration, further validating the MVP-S mechanism of action Immunogenic/inflamed tumors are more susceptible to treatment with MVP-S Potential mechanisms of primary resistance to treatment were identified ...
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating cancer therapies, based on its novel DPX platform, to treat solid and blood cancers while preserving patients’ quality of life today announced that it will hold a conference call...
Poster presentations show that: DPX generates peptide-specific, T cell-based immune responses that are more robust and more persistent than conventional water-based formulations The dual-targeted immunotherapy DPX-SurMAGE elicits a robust and specific T cel...
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing translational data obtained in the DeCidE clinical study in patients with advanced, recur...
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that two abstracts featuring two DPX-based immunotherapies have been accepted for virtual poster presentation at t...
The following slide deck was published by IMV Inc. in conjunction with this event. For further details see: IMV (IMV) presents at 2021 Wells Fargo Healthcare Virtual Conference
News, Short Squeeze, Breakout and More Instantly...
GAAP Net Income of $8.3 million or $0.25 per diluted share Non-GAAP Net Income of $11.0 million or $0.33 per diluted share Declares Third Consecutive Quarterly Dividend Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, to...
IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire - First Quarter 2023 Net Investment Income per Share of $0.46 ; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to ...